MTOR and Hypertension: One trial (NCT01150097) currently underway is investigating the effects of everolimus with CNI elimination/reduction on renal function in de novo liver transplant recipients and will also provide more information on the role of mTOR inhibitors on posttransplant diabetes and hypertension.